OnKure Therapeutics (OKUR) Amortization of Deferred Charges (2024 - 2026)
OnKure Therapeutics' (OKUR) quarterly Amortization of Deferred Charges came in at $99000.0 in Q1 2026, up 5.32% YoY from $94000.0 in Q1 2025, and up 1.02% on a QoQ basis from $98000.0 in Q4 2025.
OnKure Therapeutics (OKUR) Amortization of Deferred Charges (2024 - 2026) Analysis & Trends
OnKure Therapeutics (OKUR) has 3 years of Amortization of Deferred Charges data on file, last reported at $99000.0 in Q1 2026.
- Quarterly Amortization of Deferred Charges rose 5.32% year-over-year to $99000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $388000.0 (up 94.97% YoY) and the FY2025 annual result came in at $383000.0, up 169.72% from the prior year.
- Amortization of Deferred Charges advanced to $99000.0 in Q1 2026, from $98000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $127000.0 in Q3 2024 to a low of -$36000.0 in Q2 2024.
- A 3-year average of $69333.3 and a median of $95000.0 in 2025 frame the typical range for Amortization of Deferred Charges.
- The widest YoY moves for Amortization of Deferred Charges: up 600.0% in 2025, down 24.41% in 2025.
- Tracing OKUR's Amortization of Deferred Charges over 3 years: stood at $14000.0 in 2024, then surged by 600.0% to $98000.0 in 2025, then increased by 1.02% to $99000.0 in 2026.
- The last three Amortization of Deferred Charges figures came in at $99000.0 (Q1 2026), $98000.0 (Q4 2025), and $96000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | OnKure Therapeutics | 195.74 Mn | 19.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 101,000.00 |
| Jun 30, 2026 | 101,000.00 |
| Mar 31, 2026 | 99,000.00 |
| Mar 31, 2026 | 99,000.00 |
| Dec 31, 2025 | 98,000.00 |
| Dec 31, 2025 | 98,000.00 |
| Sep 30, 2025 | 96,000.00 |
| Sep 30, 2025 | 96,000.00 |
| Jun 30, 2025 | 95,000.00 |
| Jun 30, 2025 | 95,000.00 |
| Mar 31, 2025 | 94,000.00 |
| Mar 31, 2025 | 94,000.00 |
| Dec 31, 2024 | 14,000.00 |
| Dec 31, 2024 | 14,000.00 |
| Sep 30, 2024 | 127,000.00 |
| Sep 30, 2024 | 127,000.00 |
| Jun 30, 2024 | -36,000.00 |
| Jun 30, 2024 | -36,000.00 |
| Mar 31, 2024 | 37,000.00 |
| Mar 31, 2024 | 37,000.00 |